Advertisement

Basic Research in Cardiology

, Volume 102, Issue 5, pp 460–466 | Cite as

Endotoxin-induced effects on platelets and monocytes in an in vivo model of inflammation

  • T. Kälsch*
  • E. Elmas*
  • X. D. Nguyen
  • N. Suvajac
  • H. Klüter
  • M. Borggrefe
  • C.-E. Dempfle
ORIGINAL CONTRIBUTION

Abstract

Aims

Chronic inflammation is a major contributing factor to atherosclerosis and various markers of inflammation, fibrinolysis and coagulation are upregulated in patients with established atherosclerotic disease. The aim of this study was to investigate the direct and short-term effects of inflammation on platelet and monocyte activation with an in vivo model of endotoxemia in healthy volunteers.

Methods and results

In this study, 13 healthy male subjects with a mean age of 29.5±5.4 years received intravenous administration of lipopolysaccharide (LPS; 20 IU/kg IV). The kinetics of CD40-ligand and CD62P expression on platelets, tissue-factor binding on monocytes and platelet-monocyte aggregates were measured by whole blood flow cytometry at baseline and at 1, 2, 4, 6 and 24 hours after LPS administration. Plasma levels of soluble CD40-ligand were measured with an ELISA over the same time course. Platelet-monocyte aggregates, tissue-factor binding on monocytes and surface expression of platelet CD40L significantly increased in experimental endotoxemia in vivo, reaching peak values 1 hour after LPS administation. All values returned to baseline after 24 hours. Surface expression of CD62P on platelets and plasma levels of sCD40L did not change significantly in response to LPS.

Conclusions

In vivo administration of endotoxin leads to an activation of platelets and monocytes with an upregulation of proatherogenic CD40L on platelets. These findings underpin the role of inflammation in early atherogenesis through platelet and monocyte activation in an in vivo model.

Key words

endotoxemia atherogenesis inflammation platelets monocytes 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Amirkhosravi A, Alexander M, May K, Francis DA, Warnes G, Biggerstaff J, Francis JL (1996) The importance of platelets in the expression of monocyte tissue factor antigen measured by a new whole blood flow cytometric assay. Thromb Haemost 75:87–95PubMedGoogle Scholar
  2. 2.
    Andre P, Prasad KS, Denis CV, He M,Papalia JM, Hynes RO, Phillips DR, Wagner DD (2002) CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 8:247–252PubMedCrossRefGoogle Scholar
  3. 3.
    Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A (2002) Widespread coronary inflammation in unstable angina. N Engl J Med 347:5–12PubMedCrossRefGoogle Scholar
  4. 4.
    Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, Pestaner J, Smialek J, Virmani R (2002) Elevated Creactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 105:2019–2023PubMedCrossRefGoogle Scholar
  5. 5.
    Cipollone F, Fazia M, Iezzi A, Pini B, Cuccurullo C, Zucchelli M, De Cesare D, Ucchino S, Spigonardo F, De Luca M, Muraro R, Bei R, Bucci M,Cuccurullo F, Mezzetti A (2004) Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 109:1482–1488PubMedCrossRefGoogle Scholar
  6. 6.
    Erbel C, Sato K, Meyer FB, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM (2007) Functional profile of activated dendritic cells in unstable atherosclerotic plaque. Basic Res Cardiol 102:123–132PubMedCrossRefGoogle Scholar
  7. 7.
    Götz AK, Zahler S, Stumpf P, Welsch U, Becker BF (2005) Intracoronary formation and retention of micro aggregates of leukocytes and platelets contribute to postischemic myocardial dysfunction. Basic Res Cardiol 100:413–421PubMedCrossRefGoogle Scholar
  8. 8.
    Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM (2000) Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 102:1000–1006PubMedGoogle Scholar
  9. 9.
    Garlichs CD, John S, Schmeisser A, Eskafi S, Stumpf C, Karl M, Goppelt- Struebe M, Schmieder R, Daniel WG (2001) Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104:2395–2400PubMedGoogle Scholar
  10. 10.
    Garlichs CD, Eskafi S, Raaz D, Schmidt A, Ludwig J, Herrmann M, Klinghammer L, Daniel WG, Schmeisser A (2001) Patients with acute coronary syndromes express enhanced CD40 ligand/ CD154 on platelets. Heart 86:649–655PubMedCrossRefGoogle Scholar
  11. 11.
    Harb TS, Zareba W, Moss AJ, Ridker PM, Rifai N, Marder VJ, Miller-Watelet L, THROMBO Investigators (2003) Association between inflammatory markers, hemostatic, and lipid factors in postinfarction patients. Am J Cardiol 91:1120–1123PubMedCrossRefGoogle Scholar
  12. 12.
    Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML, the CAPTURE Study Investigators (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348:1104–1111PubMedCrossRefGoogle Scholar
  13. 13.
    Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591–594PubMedCrossRefGoogle Scholar
  14. 14.
    Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, Donald AE, Palacios M, Griffin G, Deanfield JE, MacAllister RJ, Vallance P (2000) Acute systemic inflammation impairs endothelium- dependent dilatation in humans. Circulation 102:994–999PubMedGoogle Scholar
  15. 15.
    Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ (2003) CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 92:1041–1048PubMedCrossRefGoogle Scholar
  16. 16.
    Jahn J, Dalhoff K, Katus HA (2000) Coronary artery disease: an inflammatory or infectious process. Basic Res Cardiol 95:I59–I64PubMedCrossRefGoogle Scholar
  17. 17.
    Jayachandran M, Brunn GJ, Karnicki K, Miller RS, Owen WG, Miller VM (2007) In vivo effects of lipopolysaccharide and TLR4 on platelet production and activity: Implications for thrombotic risk. J Appl Physiol 102:429–433PubMedCrossRefGoogle Scholar
  18. 18.
    Kahler J, Gerth S, Schafer P, Boersma E, Koster R, Terres W, Simoons ML, Berger J, Meinertz T, Hamm CW (2001) Antibodies to chlamydial lipopolysaccharides in unstable angina pectoris. Am J Cardiol 87:1150–1153PubMedCrossRefGoogle Scholar
  19. 19.
    Kälsch T, Elmas E, Nguyen XD, Grebert N, Wolpert C, Klüter H, Borggrefe M, Haase KK, Dempfle CE (2005) Enhanced coagulation activation by in vitro lipopolysaccharide challenge in patients with ventricular fibrillation complicating acute myocardial infarction. J Cardiovasc Electrophysiol 16:858–863PubMedCrossRefGoogle Scholar
  20. 20.
    Kälsch T, Elmas E, Nguyen XD, Wolpert C, Klüter H, Borggrefe M, Haase KK, Dempfle CE (2006) Enhanced expression of platelet CD40-ligand by in vitro lipopolysaccharide-challenge in patients with ventricular fibrillation complicating acute myocardial infarction. Int J Cardiol 107:350–355PubMedCrossRefGoogle Scholar
  21. 21.
    Kälsch T, Nguyen XD, Elmas E, Grebert N, Klüter H, Borggrefe M, Dempfle CE (2006) Coagulation activation and expression of CD40 ligand on platelets upon in vitro lipopolysaccharide-challenge in patients with unstable angina. Int J Cardiol 111:217–223PubMedCrossRefGoogle Scholar
  22. 22.
    Libby P (2002) Inflammation in atherosclerosis. Nature 420(6917):868–874PubMedCrossRefGoogle Scholar
  23. 23.
    Lindmark E, Tenno T, Siegbahn A (2000) Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 20:2322–2328PubMedGoogle Scholar
  24. 24.
    Liuzzo G, Angiolillo DJ, Buffon A, Rizzello V, Colizzi C, Ginnetti F, Biasucci LM, Maseri A (2001) Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina. Circulation 103:2236–2241PubMedGoogle Scholar
  25. 25.
    Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331:417–424PubMedCrossRefGoogle Scholar
  26. 26.
    Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P (1998) Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394:200–2003PubMedCrossRefGoogle Scholar
  27. 27.
    Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P (1997) Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40- CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 94:1931–1936PubMedCrossRefGoogle Scholar
  28. 28.
    May AE, Kälsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M (2002) Engagement of glycoprotein IIb/IIIa ({alpha}IIb{beta}3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 106:2111–2117PubMedCrossRefGoogle Scholar
  29. 29.
    Ollivier V, Hammal S, Ameziane N, Labro MT, de Prost D (2005) Modulation of tissue factor expression by rapamycin and FK-506 in lipopolysaccharide- stimulated human mononuclear cells and serum-stimulated aortic smooth muscle cells. Thromb Haemost 94:46–52PubMedGoogle Scholar
  30. 30.
    Otterdal K, Pedersen TM, Solum NO (2004) Release of soluble CD40 ligand after platelet activation. Studies on the solubilization phase. Thromb Res 114:167–177PubMedGoogle Scholar
  31. 31.
    Pernerstorfer T, Hollenstein U, Hansen J, Knechtelsdorfer M, Stohlawetz P, Graninger W, Eichler HG, Speiser W, Jilma B (1999) Heparin blunts endotoxin- induced coagulation activation. Circulation 100:2485–2490PubMedGoogle Scholar
  32. 32.
    Reul RM, Fang JC, Denton MD, Geehan C, Long C, Mitchell RN, Ganz P, Briscoe DM (1997) CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation 64:1765–1774PubMedCrossRefGoogle Scholar
  33. 33.
    Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in woman. N Engl J Med 342:836–843PubMedCrossRefGoogle Scholar
  34. 34.
    Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R, Tesauro M, Sorge R, Lauro R, Violi F (2005) Shortterm treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 111:412–419PubMedCrossRefGoogle Scholar
  35. 35.
    Schonbeck U, Libby P (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109:II18–II26PubMedCrossRefGoogle Scholar
  36. 36.
    Schonbeck U, Sukhova GK, Shimizu K, Mach F, Libby P (2000) Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA 97:7458–7463PubMedCrossRefGoogle Scholar
  37. 37.
    Steiner S, Speidl WS, Pleiner J, Seidinger D, Zorn G, Kaun C, Wojta J, Huber K, Minar E, Wolzt M, Kopp CW (2005) Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111:1841–1846PubMedCrossRefGoogle Scholar
  38. 38.
    Takemoto M, Liao JK (2001) Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712–1719PubMedGoogle Scholar
  39. 39.
    Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schonbeck U (2003) Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108:1049–1052PubMedCrossRefGoogle Scholar
  40. 40.
    Zernecke A,Weber C (2005) Inflammatory mediators in atherosclerotic vascular disease. Basic Res Cardiol 100:93–101PubMedCrossRefGoogle Scholar
  41. 41.
    Zwaka TP, Hombach V, Torzewski J (2001) C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103:1194–1197PubMedGoogle Scholar

Copyright information

© Steinkopff Verlag 2007

Authors and Affiliations

  • T. Kälsch*
    • 1
  • E. Elmas*
    • 1
  • X. D. Nguyen
    • 2
  • N. Suvajac
    • 1
  • H. Klüter
    • 2
  • M. Borggrefe
    • 1
  • C.-E. Dempfle
    • 1
  1. 1.1st Dept. of Medicine, University Hospital MannheimMedical Faculty Mannheim of the University of HeidelbergMannheimGermany
  2. 2.Institute of Transfusion Medicine and ImmunologyFaculty of Clinical Medicine Mannheim, University of HeidelbergHeidelbergGermany

Personalised recommendations